Transcriptional profile in afferent lymph cells following vaccination with liposomes incorporating CpG

Immunology

Volumn 144, Issue 3, 2015, Pages 518-529

  Neeland, Melanie R ^a   Elhay, Martin J ^b   Powell, David R ^a,c   Rossello, Fernando J ^a,c   Meeusen, Els N T ^a   de Veer, Michael J ^a  

^a MONASH UNIVERSITY   (Australia)

^b ZOETIS   (United States)

^c Life Sciences Computation Centre   (Australia)

Author keywords

cell trafficking; innate lymphoid cells; molecular biology; Toll like receptors; vaccination

Indexed keywords

EID: 84977749977     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/IMM.12401     Document Type: Article

References (61)

1. Neeland MR, Meeusen EN, de Veer MJ. Afferent lymphatic cannulation as a model system to study innate immune responses to infection and vaccination. Vet Immunol Im-munopathol 2014; 158:86–97.
2. de Veer M, Kemp J, Chatelier J, Elhay MJ, Meeusen EN. Modulation of soluble and particulate antigen transport in afferent lymph by monophosphoryl lipid A. Immunol Cell Biol 2012; 90:404–10.
3. de Veer M, Neeland M, Burke M, Pleasance J, Nathanielsz J, Elhay M, Meeusen E. Cell recruitment and antigen trafficking in afferent lymph after injection of antigen and poly (I:C) containing liposomes, in aqueous or oil-based formulations. Vaccine 2013; 31:1012–8.
4. de Veer M, Kemp J, Chatelier J, Elhay MJ, Meeusen EN. The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant. Vaccine 2010; 28:6597–602.
5. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immu-nol 2001; 167:3324–8.
6. Shargh VH, Jaafari MR, Khamesipour A, Jaafari I, Jalali SA, Abbasi A, Badiee A. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine 2012; 30:3957– 64.
7. Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, Bosio C, Dow S. Efficient immu-nization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006; 176:7335–45.
8. Jaafari MR, Badiee A, Khamesipour A et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007; 25:6107–17.
9. Wang C, Zhuang Y, Zhang YJ et al. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 2012; 30: 4790–9.
10. Kamath AT, Mastelic B, Christensen D et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J Immunol 2012; 188:4828–37.
11. Lonez C, Vandenbranden M, Ruysschaert JM. Cationic liposomal lipids: from gene car-riers to cell signaling. Prog Lipid Res 2008; 47:340–7.
12. Ma YF, Zhuang Y, Xie XF, Wang C, Wang F, Zhou DM, Zeng JQ, Cai LT. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 2011; 3:2307–14.
13. 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother Radiopharm 2001; 16:411–9.
14. Nordly P, Madsen HB, Nielsen HM, Foged C. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with im-munostimulators. Expert Opin Drug Deliv 2009; 6:657–72.
15. Burke ML, Veer MD, Pleasance J, Neeland M, Elhay M, Harrison P, Meeusen E. Innate immune pathways in afferent lymph following vaccination with poly(I:C)-containing liposomes. Innate Immun 2013; 20:501–10.
16. Neeland MR, Elhay MJ, Nathanielsz J, Meeusen EN, de Veer MJ. Incorporation of CpG into a liposomal vaccine formulation increases the maturation of antigen-loaded dendritic cells and monocytes to improve local and systemic immunity. J Immunol 2014; 192:3666–75.
17. Dobin A, Davis CA, Schlesinger F et al. STAR: ultrafast universal RNA-seq aligner. Bio-informatics 2013; 29:15–21.
18. DeLuca DS, Levin JZ, Sivachenko A et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 2012; 28:1530–2.
19. Anders S, Pyl PT, Huber W. HTSeq — a Python framework to work with high-throughput sequencing data. Bioinformatics 2014:1–5.
20. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 2012; 40:4288–97.
21. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol 2010; 11:R25.
22. Griffith M, Griffith OL, Mwenifumbo J et al. Alternative expression analysis by RNA sequencing. Nat Methods 2010; 7:843–7.
23. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001; 69:912–20.
24. Yanai H, Savitsky D, Tamura T, Taniguchi T. Regulation of the cytosolic DNA-sensing system in innate immunity: a current view. Curr Opin Immunol 2009; 21:17–22.
25. Kim WK, Hwang HR, Kim do H et al. Glycoproteomic analysis of plasma from patients with atopic dermatitis: CD5L and ApoE as potential biomarkers. Exp Mol Med 2008; 40:677–85.
26. Lattin JE, Schroder K, Su AI et al. Expression analysis of G Protein-Coupled Receptors in mouse macrophages. Immunome Res 2008; 4:5.
27. Knuehl C, Seelig A, Brecht B, Henklein P, Kloetzel PM. Functional analysis of eukary-otic 20S proteasome nuclear localization signal. Exp Cell Res 1996; 225:67–74.
28. Cobb D, Guo S, Smeltz RB. CpG and interleukin-15 synergize to enhance IFN-γ production by activated CD8+ T cells. Biomed Res Int 2013; 2013:924023.
29. + T cells are augmented in varying degrees by CpG ODN, PolyI: C and R848. Vaccine 2011; 29:6670–8.
30. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472:481–5.
31. Zhou A, Paranjape JM, Der SD, Williams BR, Silverman RH. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 1999; 258:435–40.
32. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector func-tions. Curr Opin Virol 2011; 1:519–25.
33. Cheon H, Holvey-Bates EG, Schoggins JW et al. IFN β-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J 2013; 32:2751–63.
34. Steinhagen F, Meyer C, Tross D, Gursel M, Maeda T, Klaschik S, Klinman DM. Activation of type I interferon-dependent genes characterizes the “core response” induced by CpG DNA. J Leukoc Biol 2012; 92:775–85.
35. Tross D, Petrenko L, Klaschik S, Zhu Q, Klinman DM. Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3. Mol Immunol 2009; 46:2557–64.
36. Nichani AK, Kaushik RS, Mena A et al. CpG oligodeoxynucleotide induction of antiviral effector molecules in sheep. Cell Immunol 2004; 227:24–37.
37. Caskey M, Lefebvre F, Filali-Mouhim A et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 2011; 208:2357–66.
38. Gaucher D, Therrien R, Kettaf N et al. Yellow fever vaccine induces integrated multilin-eage and polyfunctional immune responses. J Exp Med 2008; 205:3119–31.
39. Fossum C, Hjertner B, Ahlberg V et al. Early inflammatory response to the saponin adjuvant Matrix-M in the pig. Vet Immunol Immunopathol 2013; 158:53–61.
40. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003; 101:4500–4.
41. Geherin SA, Fintushel SR, Lee MH et al. The skin, a novel niche for recirculating B cells. J Immunol 2012; 188:6027–35.
42. Spits H, Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012; 30:647–75.
43. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44–9.
44. Souza-Fonseca-Guimaraes F, Parlato M, de Oliveira RB et al. Interferon-γ and granulo-cyte/monocyte colony-stimulating factor production by natural killer cells involves different signaling pathways and the adaptor stimulator of interferon genes (STING). J Biol Chem 2013; 288:10715–21.
45. Booth JS, Nichani AK, Benjamin P, Dar A, Krieg AM, Babiuk LA, Mutwiri GK. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Vet Immunol Immunopathol 2007; 115:24–34.
46. Lund H, Boysen P, Hope JC, Sjurseth SK, Storset AK. Natural killer cells in afferent lymph express an activated phenotype and readily produce IFN-γ. Front Immunol 2013; 4:395.
47. Barber GN. Cytoplasmic DNA innate immune pathways. Immunol Rev 2011; 243:99– 108.
48. Klaschik S, Tross D, Klinman DM. Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukoc Biol 2009; 85:788–95.
49. Xu Y, Johansson M, Karlsson A. Human UMP-CMP kinase 2, a novel nucleoside monophosphate kinase localized in mitochondria. J Biol Chem 2008; 283:1563–71.
50. Xiao H, Shan L, Zhu H, Xue F. Detection of significant pathways in osteoporosis based on graph clustering. Mol Med Rep 2012; 6:1325–32.
51. York MR. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists (vol 56, pg 1010, 2007). Arthritis Rheum 2007; 56:1675.
52. Jin P, Han TH, Ren JQ, Saunders S, Wang E, Marincola FM, Stroncek DF. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010; 8:4.
53. Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 2004; 1695:225–33.
54. Hope JC, Guzman E, Cubillos-Zapata C et al. Migratory sub-populations of afferent lymphatic dendritic cells differ in their interactions with Mycobacterium bovis Bacille Calmette–Guerin. Vaccine 2012; 30:2357–67.
55. Yang CY, Chen JB, Tsai TF et al. CLEC4F is an inducible C-type lectin in F4/80-posi-tive cells and is involved in α-galactosylceramide presentation in liver. PLoS ONE 2013; 8:e65070.
56. Mortezai N, Behnken HN, Kurze AK, Ludewig P, Buck F, Meyer B, Wagener C. Tumor-associated Neu5Ac-Tn and Neu5Gc-Tn antigens bind to C-type lectin CLEC10A (CD301, MGL). Glycobiology 2013; 23:844–52.
57. Richards KH, Macdonald A. Putting the brakes on the anti-viral response: negative reg-ulators of type I interferon (IFN) production. Microbes Infect 2011; 13:291–302.
58. Weaver LK, Behrens EM. A158: CpG-induced macrophage activation syndrome devel-ops through an organism level resistance to toll-like receptor 9 tolerance. Arthritis Rheumatol 2014; 66(Suppl. 11):S204.
59. Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, Kambayashi T, Kore-tzky GA. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Investig 2011; 121:2264–77.
60. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243:136–51.
61. + T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J Control Release 2011; 150:307–17.